CTRI/2020/01/022983尚未招募未知
A Parallel Group, Double-Blind, Randomized Controlled Trial to assess the optimum dose of ketamine infusion in management of early postoperative pain in Elective Laparoscopic Cholecystectomy
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Age group between 18-65 years.
- •2) ASA grade I to II.
- •3) Patients posted for Elective laproscopic cholecystectomy under General
排除标准
- •1) Psychiatric disorders such as schizophrenia and acute psychoses.
- •2) Patients with features of raised IntraCranial Pressure
- •3) Penetrating Eye injury and increased IntraOcular Pressure.
- •4) Regular use of anti-inflammatory drugs (NSAIDs)
- •5) Chronic pain syndromes
- •6) Acute or chronic alcohol intoxication
- •7) Chronic kidney disease, Chronic Liver disease
- •8) Moderate to severe hypertension 9) Acute Porphyria
- •10) History of CErebroVascular accident
- •11) Intolerance or allergy to S(+)-ketamine
- •12) Any patients below 18 years old and above 65 years old
- •13) Any drug allergy.
- •14) Any emergency surgery.
研究者
相似试验
已完成
不适用
Randomized, Double Blind, Parallel Group, Controlled with Placebo Study performed Under Internal Blind Conditions whose Purpose is to Examine the Safety, Tolerability and Efficacy of MK-0869 for the Prevention of Nausea and Vomiting Induced by Chemotherapy Associated with Administration of High doses of Cisplatin.-C80 Malignant neoplasm, without specification of siteMalignant neoplasm, without specification of siteC80PER-009-01MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
1 期
Efficacy of a herbal drug called CLR” compared to the antibiotic fosfomycin trometamol” in acute lower urinary tract infectionsAcute lower uncomplicated urinary tract infectionMedDRA version: 20.0Level: LLTClassification code 10024981Term: Lower urinary tract infectionSystem Organ Class: 100000004862EUCTR2013-004529-99-DEBionorica SE644
进行中（未招募）
不适用
A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate theClinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with RheumatoidArthritis Having an Inadequate Response to Methotrexate.Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 19-Dec-2007);Revised Protocol 02, incorporating administrative letter 01 and amendment 03 (version 1.0, dated 12-Mar-2008) and Amendment 07 (version 1.0 dated on 01-Jul-2008).subjects with rheumatoid arthritis (RA) who are on background therapy with methotrexate (MTX)MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2008-000170-20-CZBristol Myers Squibb International Corporation240
进行中（未招募）
1 期
A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate theClinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with RheumatoidArthritis Having an Inadequate Response to Methotrexate.Revised Protocol 01, incorporating administrative letter 01 and amendment 03 (version 1.0, dated 12-Mar-2008)Estudio aleatorizado, de grupos paralelos, en doble ciego y controlado con placebo, para evaluar la eficacia clínica y la seguridad de BMS-582949 administrado por vía oral a sujetos con artritis reumatoide que han mostrado respuesta inadecuada al metotrexato.Protocolo Revisado 01, que incorpora la carta administrativa 01 y la enmienda 03 (version 1.0, de fecha 12-Mar-2008).subjects with rheumatoid arthritis (RA) who are on background therapy with methotrexate (MTX)sujetos con artritis reumatoide (AR) que estan recibiendo tratamiento de fondo con metotrexato (MTX).MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2008-000170-20-ESBristol Myers Squibb International Corporation240
进行中（未招募）
1 期
A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate theClinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with RheumatoidArthritis Having an Inadequate Response to Methotrexate.Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 19-Dec-2007);Revised Protocol 01, incorporating administrative letter 01 and amendment 03 (version 1.0, dated 12-Mar-2008)subjects with rheumatoid arthritis (RA) who are on background therapy with methotrexate (MTX)MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2008-000170-20-FRBristol Myers Squibb International Corporation240